Praxis Program Nets $1.8M Savings
Praxis, the Brentwood, TN-based centralized patient recruitment and retention company, announced the status of a current recruitment and retention program for a top pharmaceutical company currently studying a mental health issue in Phase III.
Praxis is providing services for two studies in Phase III, for which it had successfully completed a prior Phase III recruitment initiative. While the trials seek different patient populations, they are complimentary. Because of this, Praxis was able to develop an umbrella program for the sponsor under which both protocols can be effectively and simulatneously recruited. Based on the umbrella program, the sponsor was able to save $1.8 million in clinical program costs.
Praxis used both past experience in mental health studies, with the predictive modleing of its PraxisDirect 2.0 software to design the program to meet enrollment goals. Nearly 2,000 patients will be randomized across 75 sites within a nine-month period. Praxis has experience with mental health areas including bipolar depression, major depressive disorder (MDD), and bipolar mania.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
